[Prostaglandin F2alpha as a method of choice for interruption of pregnancy (author's transl)].
Since March 1972 we have been applying Prostaglandin F2 alpha in 6 patients between the 8th and 12th week of pregnancy, in 2 patients between the 13th and 16th week, in 16 patients from the 17th week onwards, and in 10 women at term. The intravenous and extraamniotic application of Prostaglandin for interruption of pregnancy has proved a success even in severe general diseases. No severe side effects have been observed. Antidotes are beta-sympathicomimetics as for Oxytocin, too Prostaglandin is a valuable pharmacon in the obstetrical area.
D000028:Abortion, Induced / Q000379:methods*; D000293:Adolescent; D000328:Adult; D000653:Amniotic Fluid; D003093:Colitis, Ulcerative; D005260:Female; D005313:Fetal Death; D006801:Humans; D006828:Hydatidiform Mole; D007275:Injections, Intravenous; D007951:Leukemia, Myeloid; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic; D011251:Pregnancy Complications, Infectious; D011261:Pregnancy Trimester, First; D011460:Prostaglandins F / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012409:Rubella
D011460:Prostaglandins F
Prostaglandin F2 alpha als Mittel der Wahl zum Schwangerschaftsabbruch